Short answer
AVANOS MEDICAL, INC. (AVNS) filed an 8-K current report with the SEC on July 22, 2026 reporting Item 5.07 (Submission of Matters to a Vote of Security Holders), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Merger approved overwhelmingly: 35,119,793 votes for versus 32,508 against.
AVANOS MEDICAL, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.07 · Submission of Matters to a Vote of Security Holders
- Merger approved overwhelmingly: 35,119,793 votes for versus 32,508 against
- Transaction approval clears the primary shareholder condition for Parent’s acquisition of Avanos
- 35,207,549 shares represented, equal to approximately 75.15% of outstanding shares
- Merger-related executive compensation approved on advisory basis, 30,620,395 votes for
- Adjournment proposal unnecessary because sufficient votes supported the merger
Item 7.01 · Regulation FD Disclosure
- Stockholders approved and adopted the Merger Agreement at the Special Meeting
- Approved merger transactions can proceed toward closing, subject to remaining conditions
- July 22, 2026 press release provides the company’s detailed transaction update
Item EX-99.1 · Exhibit EX-99.1
- Stockholders approved AIP’s acquisition with 99.75% of voted shares supporting the transaction
- Approval represented 74.96% of total outstanding shares as of June 18, 2026
- Consideration fixed at $25.00 cash per Avanos share, limiting remaining deal-value uncertainty
- All required regulatory approvals received; closing expected by July 27, 2026, subject to customary conditions
- Completion would transition Avanos to AIP ownership and remove public-market exposure for shareholders
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other AVANOS MEDICAL, INC. 8-K filings
Get the next AVNS 8-K as it lands
Follow AVNS for push alerts, or ask the research agent what this filing means.